Natural Resources for Human Health
eISSN: 2583-1194

Original Research

**Received** 15 March 2026
**Revised** 18 April 2026
**Accepted** 09 May 2026

Natural Resources for Human Health 2026, Vol. 6 (3): 432–439

**KEYWORDS**:
Andrographis paniculata; Andrographolide; Antiplasmodial; Malaria; Drug-resistant parasites; Plasmodium falciparum; Diterpenoids; Antimalarial activity; Medicinal plants; Phytotherapy.

# Antiplasmodial Screening of Andrographis paniculata Diterpenoids Against Drug-Resistant Parasites

Durga Paswan[1], Maryam Sheranova [2], Mahendran Arumugam3, Swarupanjali Padhi4, G.Shanthini Nachiar5, Vivek Saraswat6, M.J. Haja Abdul Nazeer7, Vidhya Lakshmi8

[1]Department of Anatomy, Noida international University, Greater Noida, Uttar Pradesh 203201, India., durgapaswan@gmail.com
[2]Associate Professor, Pedagogical Department, Jizzakh State Pedagogical University email: komila8866@gmail.com
[3]Center for Global Health Research, Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences, Chennai, India, mahendrana.sdc@saveetha.com
[4]Associate Professor, Department of Pharmaceutics, Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida, Uttar Pradesh, India, swarupanjali.pharmacy@niet.co.in, 0000-0002-2200-5542
[5]Assistant Professor, School of pharmacy, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India, shanthini.pharmacy@sathyabama.ac.in, 0000-0002-4907-2289
[6]Centre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, 140401, Punjab, India. vivek.saraswat.orp@chitkara.edu.in https://orcid.org/0009-0000-6875-1255
[7]Professor Department of Microbiology Vinayaka Missions Medical College, Karaikal Vinayaka Mission's Research Foundation (DU), Tamil Nadu, India. haja.nazeer@yahoo.com 0000-0001-6006-0708
[8]Pharmacology, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research, Enathur, Kanchipuram, Tamil Nadu 631552, vidhyalakshmi@maher.ac.in

**ABSTRACT:** Background: Selectivity and activity data at the fraction level can be used to prioritize diterpenoid leads to medicinal-chemistry optimization. Objective: To compare purified andrographolide-rich diterpenoid fractions with reference compounds of chloroquine and artesunate using an in-vitro parasite-screening assay. Methods: The experimental protocol was drafted with 24 experimental units or participants with chloroquine sensitive 3D7 and multidrug resistant K1 Plasmodium falciparum cultures. The duration of the intervention or test was 72 hours. The main result was the growth of parasites IC50, and further evaluation of selectivity index, stage-selective inhibition, hemozoin formation, and combination index with artesunate. The standardized laboratory, clinical, or food-analysis procedures were used, and the effects of between conditions were assessed using two-sided tests at $\alpha$=0.05. Results: Diterpenoid fraction A was the most active with an IC50 of 2.9 µM against 3D7 and 4.8 µM against resistant K1 parasites, and a selectivity index of 17.9. A synergistic effect was obtained between fraction A and artesunate (combination index 0.58), which allowed a 2.4-fold reduction in dose and 95 ± 2% parasite clearance after 48 hours.

Natural Resources for Human Health
eISSN: 2583-1194

The direction and the extent of the dummy results were internally consistent in both primary and secondary endpoints and tolerability or assay-quality metrics were satisfactory. Conclusion: The example dataset suggests that purified andrographolide-rich diterpenoid fractions could produce a meaningful improvement in parasite growth IC50 through interference with parasite redox homeostasis, membrane processes, and heme detoxification. These findings are intended solely as a complete manuscript-development example and require replacement with ethically generated, independently verified observations before scientific submission. Keywords: Andrographis paniculata; andrographolide; malaria; drug resistance; antiplasmodial.

## 1. INTRODUCTION

Antiplasmodial Screening of Andrographis paniculata Diterpenoids Against Drug-Resistant Parasites addresses an important question at the interface of experimental pharmacology, nutritional science, and translational health research. Directly relevant published work has established a scientific basis for evaluating purified andrographolide-rich diterpenoid fractions in relation to parasite growth IC50 [1]. Nevertheless, variations in preparation, exposure, comparator selection, and outcome definition continue to limit confident comparison across studies.

A second line of evidence supports the biological plausibility of the present hypothesis Previous studies conducted on Andrographis paniculata and related compounds have shown some functional or biochemical activity that is in line with the proposed benefit [2]. These observations lend themselves to formal testing, but do not exclude the need for standardized materials and pre-determined analytical criteria.

Natural-product and functional-food literature pointed to the need for reproducibility, which involves both chemical characterization and processing conditions, dose, biological matrix, and stability of active constituents [3]. In the current study, andrographolide-enriched diterpenoid fractions were therefore not considered as an undefinable traditional or commercially available formulation, but as an intervention for research purposes.

The suggested mechanism includes interference with parasites' redox homeostasis, membrane processes, and heme detoxification. The biological responses that are related to the disease process frequently include interacting redox, inflammatory, metabolic, microbial, enzymatic or differentiation pathways, but not a single target.The biological responses that are related to the disease process usually involve interacting redox, inflammatory, metabolic, microbial, enzymatic or differentiation pathways and not a single target [4]. Therefore, a more coherent interpretation of measurement of a primary functional endpoint and mechanistic markers can be obtained.

In addition, there is a need for assessment methods appropriate to the model used for the study. Standardized sample handling, validated analytical procedures, use of appropriate controls, prespecified interpretation threshold - established methodology, laboratory or clinical [5]. These principles were used to select parasite growth IC50 as the main parameter and secondary parameters.

In cases where changes in parasite growth IC50 is accompanied by concordantly changed selectivity index and stage-specific inhibition, the change is most convincing. According to related research, integrated assessment of functional, biochemical and structural outcomes is a valuable method for the assessment of complex botanical, microbial or food-based interventions [6].

Safety and quality are both important. Natural origin does not ensure a consistent composition nor eliminates possibility of adverse effects, contaminants, interactions and degradation, and published pharmacovigilance and quality-control evidence suggests to integrate these in the early phase of product development [7].

Lastly, the study design must be transparent to minimize the bias. Recommendations for the experimental model in the present study are supported by guidance and previous methodological studies that include randomization, blinding as appropriate, replication, complete documentation of exclusion of subjects from the analyses, and reporting of effect estimates, not just p-Values [8].

Few studies have included a well-defined purified androgagrapholide-rich diterpenoid fraction, an appropriate comparator, a prespecified primary endpoint and supporting mechanistic or feasibility outcomes in chloroquine-sensitive 3D7 and multi-drug resistant K1 Plasmodium falciparum cultures. Thus, the current study sought to assess the purified andrographolide enriched fractions of diterpenoids for their IC50 in the growth of parasites compared with chloroquine and artesunate reference drugs. The secondary objective was to assess selectivity index, stage-specific inhibition, hemozoin formation and quality/safety-related parameters.

## 2. MATERIALS AND METHODS

### 2.1. Study design and setting

This paper presents a pre-defined controlled in-vitro parasite-screening experiment that compared chloroquine-sensitive 3D7 and multidrug-resistant K1 Plasmodium falciparum cultures. This was to be designed as 24 experimental units or participants to compare purified andrographolide-rich diterpenoid fractions with chloroquine and artesunate reference compounds. The time of observation was 72 hours. The numbers in this manuscript are all dummy/example data designed to be used in the writing, statistical demonstration, table building, and graph design; they are not the numbers of an actual completed investigation. The design is however based on realistic laboratory or clinical procedures so that the draft could be later modified to an approved protocol and substituted by real measurements.

### 2.2. Experimental material and test system

Biological testing was preceded by the authentication and standardization of the test material. Purified andrographolide-enriched diterpenoid fractions was made in a solvent system that was found not to influence the assay at the final concentration. The experimental system consisted of chloroquine sensitive 3D7 and multidrug resistant K1 cultures of Plasmodium falciparum. Separate experiments were carried out on different days and technical replicas were carried out within the experiment. Appropriate conditions included untreated, vehicle, injury or growth and reference-comparator conditions.

### 2.3. Concentration selection and exposure

Non-precipitating, assay-compatible concentrations were determined, and the upper exposure limit was determined, in a preliminary range-finding experiment. The primary experiment involved a concentration gradient of low, intermediate, and high concentrations of the range of concentrations expected to be active. The exposure was 72 hours. Plates, culture flasks or assay tubes were assigned according to randomized layout and positions at the edges were equalized across conditions to reduce systematic plate effects.

### 2.4. Outcome assessment

The most significant product was the growth of parasites IC50 in μM. Secondary outcomes were selectivity index, stage specific inhibition, hemozoin formation and combination index with artesunate. Depending on the design, measurements were done at baseline and follow-up or at concentration and time conditions. Assays were done as per the validated kit guidelines or standardized assays with duplication of measurements and coefficient of variation that were above 10%. The clinical measurements were taken following a standardized rest period and the results of food-products were evaluated under controlled serving conditions.

### 2.5. Quality assurance and bias control

A written laboratory/trial manual delineated protocol deviation, sample labeling, timing constraints, calibration, data entry, and protocol deviations. Outcome assessors were blinded when the format of interventions allowed. Conceptual recheck of records versus source data was also performed on ten percent of records and analytical runs were only accepted where calibration and quality-control samples fell within predetermined limits. The primary complete-case display did not impute missing values; sensitivity analyses were conducted based on an intention-to-treat framework or model-based estimation in case of missing values.

### 2.6. Sample-size rationale

The sample used was planned to be 24 units to give a realistic precision of a manuscript-development example. To carry out a real study, the calculation must be substituted by some calculation based on an estimated standard deviation provided by pilots

and the smallest clinically or biologically significant difference in parasite growth IC50. The last calculation must state two-sided $\alpha$=0.05, power desired at least 80, ratio of allocation, expected attrition or unusable assays and any modifications to repeated measures, clustering, or multiple primary comparisons.

### 2.7. Statistical analysis

Continuous data were summarized as mean ± standard deviation when approximately normally distributed and as median with interquartile range when skewed. Categorical outcomes were reported as number and percentage. Between-group baseline comparisons used independent t tests, Mann-Whitney tests, chi-square tests, or Fisher exact tests as appropriate. Primary outcomes were assessed with analysis of covariance, repeated-measures analysis, mixed-effects models, one-way analysis of variance with multiplicity-adjusted post hoc comparisons, or nonparametric equivalents according to design. Effect estimates were accompanied by 95% confidence intervals. Correlations used Pearson or Spearman coefficients. All tests were two-sided, and $p<0.05$ was considered statistically significant. Analyses were conceptually performed in a current statistical package with an auditable syntax file.

## 3. RESULTS

The analysis included the full dummy/example dataset specified for the controlled in-vitro parasite-screening study. Baseline characteristics, assay controls, or starting values were balanced across comparison conditions, and no predefined quality-control run was rejected. The tables present mean ± standard deviation unless another summary is stated. Because the data are illustrative, participant flow, assay exclusions, and p-values were generated to be statistically coherent rather than to represent an actual enrolled sample.

Diterpenoid fraction A showed the greatest activity, with IC50 values of 2.9 µM against 3D7 and 4.8 µM against resistant K1 parasites, while maintaining a selectivity index of 17.9.

**Table 1.** Antiplasmodial activity and selectivity

| Compound | 3D7 IC50 (µM) | K1 IC50 (µM) | CC50 (µM) | Selectivity index K1 |
|---|---|---|---|---|
| Andrographolide | 3.8 | 5.6 | >100 | >17.9 |
| 14-deoxyandrographolide | 7.1 | 9.4 | >100 | >10.6 |
| Diterpenoid fraction A | 2.9 | 4.8 | 86 | 17.9 |
| Diterpenoid fraction B | 5.4 | 6.7 | >100 | >14.9 |
| Chloroquine | 0.04 | 0.62 | >50 | >80.6 |
| Artesunate | 0.01 | 0.02 | >50 | >2500 |

Values are dummy/example data presented as mean ± SD unless otherwise stated.

The direction of the primary effect was supported by changes in selectivity index and stage-specific inhibition. The magnitude of response generally increased with intervention exposure or was greater at follow-up in the intervention arm, while the comparator showed smaller changes. Where repeated measurements were available, the group-by-time or condition effect remained significant after adjustment for baseline values and planned multiple comparisons.

**Table 2.** Stage-specific inhibition at 2×IC50

| Compound | Ring stage (%) | Trophozoite (%) | Schizont (%) | Hemozoin inhibition (%) |
|---|---|---|---|---|
| Andrographolide | 72 ± 6 | 81 ± 5 | 67 ± 7 | 48 ± 6 |

| | | | | |
|---|---|---|---|---|
| 14-deoxyandrographolide | 58 ± 7 | 69 ± 6 | 54 ± 7 | 37 ± 5 |
| Diterpenoid fraction A | 76 ± 6 | 84 ± 5 | 72 ± 6 | 55 ± 6 |
| Diterpenoid fraction B | 65 ± 7 | 73 ± 6 | 60 ± 7 | 42 ± 5 |
| Chloroquine | 61 ± 7 | 74 ± 6 | 79 ± 5 | 31 ± 5 |
| Artesunate | 88 ± 5 | 92 ± 4 | 95 ± 3 | 68 ± 6 |

Values are dummy/example data presented as mean ± SD unless otherwise stated.

Fraction A combined synergistically with artesunate (combination index 0.58), permitting a 2.4-fold dose reduction and achieving 95 ± 2% parasite clearance at 48 hours.




**Figure 1.** Primary outcome based on dummy/example data.

Exploratory analyses indicated that the response in parasite growth IC50 was associated with the most relevant mechanistic marker. The pattern was consistent with interference with parasite redox homeostasis, membrane processes, and heme detoxification. No extreme value altered the direction of the result in sensitivity analysis. For clinical and food studies, adherence and acceptability remained within predefined feasibility limits; for laboratory studies, replicate variation and control performance remained within the planned analytical range.

**Table 3.** Combination with artesunate in K1 parasites

| Diterpenoid | Combination index | Dose reduction index | Parasite clearance at 48 h (%) | Interpretation |
|---|---|---|---|---|
| Andrographolide | 0.62 | 2.1 | 93 ± 3 | Synergistic |
| 14-deoxyandrographolide | 0.84 | 1.5 | 88 ± 4 | Additive |
| Fraction A | 0.58 | 2.4 | 95 ± 2 | Synergistic |
| Fraction B | 0.79 | 1.6 | 90 ± 3 | Additive |

Values are dummy/example data presented as mean ± SD unless otherwise stated.




**Figure 2.** Secondary or mechanistic outcome based on dummy/example data.

No unexpected safety signal was present in the example dataset. Mild events or assay artifacts were infrequent and balanced, and there were no serious adverse events, unplanned deaths, contamination failures, or invalid control runs unless explicitly shown in the tables. These observations are illustrative and must not be interpreted as evidence of real-world safety.

## 4. DISCUSSION

The present manuscript-development study indicates that purified andrographolide-rich diterpenoid fractions may improve parasite growth IC50 compared with chloroquine and artesunate reference compounds. The dummy findings were strengthened by concordant changes in selectivity index, stage-specific inhibition, and hemozoin formation. The significance of this internal consistency is that the fact that different functional and mechanistic endpoints agree is less likely to be an indication of isolated analytical variation.

The trend of the major outcome is generally congruent with other published studies on standardized botanical or food-derived interventions in other models [9]. In spite of the protocols and populations, that literature also suggests that the quality and dose of preparation can have a significant effect on the magnitude of response.

Similar research has also documented the shifts in inflammatory, oxidative, metabolic, microbial, structural or functional outcomes which justify multidimensional assessment instead of a single surrogate endpoint [10]. The current trend thus complies with a broader evidence base and still is specific to the intervention and model under consideration.

Mechanistic interpretation is evidenced by studies that show complex interventions can have convergent paths and effects dependent on the matrix [11]. The correlation between the primary response and supporting markers in this study was consistent with interference with the redox homeostasis of parasites, membrane processes, and heme detoxification, but no correlation alone can be used to support the mediation nor the active constituent.

The clinical or biological applicability of selectivity index and stage specific inhibition is further supported by previous work with related endpoints [12]. The hypothesis is reinforced by their parallel improvement, but confirmatory research in the future needs to prespecify whether the variables are secondary outcomes, mechanistic mediators or exploratory biomarkers.

The magnitude of the example effect needs to be taken in the context of previous intervention research and evidence syntheses within the field [13]. The scale was also purposefully realistic and there was overlap in the individuals or duplication since pilot effects often decrease when experimented in larger independent samples.

The methodological evidence underlines the role of standardized measurement, proper conditions of comparison, and transparent reporting of the research of complex interventions [14]. Some sources of bias can be minimized by replication, allocation concealment, blinded assessment, crossover control, or validated analytical calibration but none can eliminate all sources of error.

The tolerability, quality assurance, product stability, adherence, and interactions with habitual diet or medication are also a requirement of long-term translation. Published safety and implementation literature advocates consideration of these factors, in addition to efficacy, instead of once an encouraging initial outcome is received [15].

There are a number of limitations to the study. To begin with, the numerical data is descriptive and cannot be used to form a scientific statement. Second, the proposed sample and time might fail to find rare adverse events or protracted adaptation. Third, surrogate outcomes are not necessarily patient-important benefits. Fourth, dietary, genetic, microbial, environmental, harvest or manufacturing factors are not measured, and can alter response.

Independent analytical validation, dose-ranging, preregistration, sufficient power, and predefined statistical analysis plan should be included in further research. The data of ethics approval, trial registration, allocation procedures, adherence, and intention-to-treat analysis should be reported in clinical studies. Reported preclinical studies must include randomization, blinding, humane endpoints, exclusions and batch level chemical fingerprints.

From a translational perspective, fraction-level activity and selectivity data can prioritize diterpenoid leads for medicinal-chemistry optimization. The intervention should be considered a potential adjunct or research lead rather than a replacement for established care. Replication, safety, cost, standardization, acceptability, and comparison with available alternatives should determine whether further development is justified.

Overall, the example findings support the study hypothesis and provide a coherent structure for a genuine investigation. Every numerical result, ethics statement, registration detail, disclosure, and analysis should be replaced or verified against the actual study record before scientific submission.

## 5. CONCLUSION

In this complete manuscript draft using dummy/example data, purified andrographolide-rich diterpenoid fractions produced a favorable change in parasite growth IC50 compared with chloroquine and artesunate reference compounds, with supporting changes in selectivity index, stage-specific inhibition, and hemozoin formation. The pattern was consistent with interference with parasite redox homeostasis, membrane processes, and heme detoxification and suggested potential relevance because fraction-level activity and selectivity data can prioritize diterpenoid leads for medicinal-chemistry optimization. The draft gives a logical ground on which to build protocols, plans to collect data, and subsequent manuscript development; although any numerical results will have to be substituted with ethically produced and externally validated data before the work can be presented as original research.

**Declarations for Completion Before Submission**

**Ethics approval:** Insert the actual institutional ethics committee name, approval number, approval date, and relevant consent or animal-welfare statement.

**Trial registration:** Insert the registry name and number for prospective clinical trials, where applicable.

**Funding:** Insert the verified funding source or state that no specific funding was received.

**Conflicts of interest:** Insert author-specific conflict-of-interest disclosures.

**Data availability:** Describe where the actual de-identified dataset and analysis code will be available.

**Author contributions:** Insert contribution statements using an accepted taxonomy such as CRediT.

## REFERENCES

[1] Mishra K, Dash AP, Dey N. Andrographolide: a novel antimalarial diterpene lactone compound from Andrographis paniculata and its interaction with curcumin and artesunate. J Trop Med. 2011;2011:579518. doi:10.1155/2011/579518. PMID:21760808.

[2] Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(3):770-803. doi:10.1021/acs.jnatprod.9b01285. PMID:32162523.

[3] Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, et al. Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnol Adv. 2015;33(8):1582-1614. doi:10.1016/j.biotechadv.2015.08.001. PMID:26281720.
[4] Sies H. Oxidative stress: a concept in redox biology and medicine. Redox Biol. 2015;4:180-183. doi:10.1016/j.redox.2015.01.002. PMID:25588755.
[5] Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014;4:177. doi:10.3389/fphar.2013.00177. PMID:24454289.
[6] Prior RL, Wu X, Schaich K. Standardized methods for the determination of antioxidant capacity and phenolics in foods and dietary supplements. J Agric Food Chem. 2005;53(10):4290-4302. doi:10.1021/jf0502698. PMID:15884874.
[7] Wiegand I, Hilpert K, Hancock REW. Agar and broth dilution methods to determine the minimal inhibitory concentration of antimicrobial substances. Nat Protoc. 2008;3(2):163-175. doi:10.1038/nprot.2007.521. PMID:18274517.
[8] Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003;52(1):1. doi:10.1093/jac/dkg301. PMID:12805255.
[9] Mun SH, Joung DK, Kim YS, et al. Synergistic antibacterial effect of curcumin against methicillin-resistant Staphylococcus aureus. Phytomedicine. 2013;20(8-9):714-718. PMID:23537748.
[10] Teow SY, Liew K, Ali SA, Khoo ASB, Peh SC. Antibacterial action of curcumin against Staphylococcus aureus: a brief review. J Trop Med. 2016;2016:2853045. doi:10.1155/2016/2853045. PMID:26880829.
[11] Amalraj A, Gopi S. Medicinal properties of Terminalia arjuna (Roxb.) Wight & Arn.: a review. J Tradit Complement Med. 2017;7(1):65-78. doi:10.1016/j.jtcme.2016.02.003. PMID:28053890.
[12] Mandal S, Patra A, Samanta A, et al. Analysis of phytochemical profile of Terminalia arjuna bark extract with antioxidative and antimicrobial properties. Asian Pac J Trop Biomed. 2013;3(12):960-966. PMID:24093787.
[13] Singh MK, Yadav SS, Gupta V, Khattri S. Immunomodulatory role of Emblica officinalis in arsenic-induced oxidative damage and apoptosis in thymocytes of mice. BMC Complement Altern Med. 2013;13:193. PMID:23889914.
[14] Sharma A, Sharma MK, Kumar M. Modulatory role of Emblica officinalis fruit extract against arsenic-induced oxidative stress in Swiss albino mice. Chem Biol Interact. 2009;180(1):20-30. PMID:19428342.
[15] Percie du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 2020;18(7):e3000410. doi:10.1371/journal.pbio.3000410. PMID:32663219.